Explore our downloadable clinical and biophysical whitepapers alongside an interactive, searchable library of 554 peer-reviewed studies categorized across the 5 foundational biological pillars and 12 clinical condition groups of Directed Cellular Mobility Current (EDCMC).
Select any whitepaper below to preview its quantitative highlights or complete our brief clinical registration form to immediately download the full illustrated PDF monograph.
Comprehensive synthesis of the Cellionyx Cytomotion™ V9 (V-Series) electroceutical platform across 23 clinical indications, integrating 55 hospital GE LOGIQ e Doppler captures, 6-channel Artinis PortaMon NIRS trials, and 115+ peer-reviewed references.
Multi-vessel hospital spectral Doppler ultrasound validation across 7 lower- and upper-extremity arteries and veins (Popliteal, Posterior Tibial, Dorsalis Pedis, Brachial, and Ulnar) with untreated contralateral limb control.
Simultaneous superficial (30 mm), mid-zone (35 mm), and deep muscle (40 mm) continuous-wave near-infrared spectroscopy (NIRS) quantifying capillary oxygen saturation (TSI%) and interstitial fluid evacuation.
Molecular mechanisms of Directed Cellular Mobility Current (EDCMC): transmembrane electric-field sensing via Galvanin (TMEM154), skeletal muscle AMPK–ERK -> Midkine (MDK) -> LRP1 macrophage efferocytosis, and mitochondrial biogenesis.
Detailed regulatory roadmap covering Stage 1 Class II 21 CFR § 890.5850 / 890.5860 foundational clearance (IEC 60601-1/-2-10, ISO 13485, ISO 10993) and Stage 2 multi-center IRB randomized clinical trial protocols.
Swipe or scroll horizontally across each of the 5 physiological and clinical tiers below. Click any study card to inspect the full abstract, quantitative outcomes, and direct PubMed / PMC / DOI links.
Arterial volume flow (+94.9%), capillary recruitment, VEGF-A/PLGF angiogenesis, spatially resolved NIRS, and transcutaneous oxygen tension (TcPO2).
Skeletal muscle venous-lymphatic pump activation (+114.2% to +209% peak venous velocity), post-surgical swelling reduction, DVT prophylaxis, and Starling filtration stabilization.
Diabetic (DPN), Chemotherapy-Induced (CIPN), and small-fiber neuropathy pathology, vasa nervorum rescue, anterograde mitochondrial transport, and clinical nerve reinnervation.
Electric-field cell migration (4x speed), AMPK–ERK -> Midkine -> LRP1 macrophage polarization (3.3x M2 / 5x M1 drop), IL-10/CRP modulation, and 29-RCT chronic ulcer closure.
2x–5x mitochondrial density on blinded muscle biopsy (p < 0.001), cramp threshold frequency modulation, disuse atrophy prevention, and multi-center pain RCTs.
Filter by Clinical Condition (Overuse, Sprain, Edema, Muscle Soreness / DOMS, Pain, Strain, Spasm/Cramps, Atrophy, Neuropathy, Wounds/Ulcers, Perfusion, Equine), Biological Tier, or Study Design—or search across all 554 studies by keyword, author, year, PMID, PMCID, or DOI.
Request a clinical demo to see how Cytomotion™ can integrate into your practice and revolutionize your approach to healing.